Stockscreener 앱 받기
30.96
3.03%
0.91
시간 외 거래:
30.65
-0.31
-1.00%
전일 마감가:
$30.05
열려 있는:
$29.75
하루 거래량:
161.45K
Relative Volume:
0.62
시가총액:
$790.34M
수익:
-
순이익/손실:
$-69.47M
주가수익비율:
-5.5312
EPS:
-5.5973
순현금흐름:
$-73.92M
1주 성능:
+4.88%
1개월 성능:
+6.17%
6개월 성능:
+9.44%
1년 성능:
+76.51%
1일 변동 폭
$29.70
$31.25
1주일 범위
$28.80
$31.45
52주 변동 폭
$16.54
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
명칭
Lenz Therapeutics Inc
전화
858-925-7000
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
30.96 | 790.34M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2025-03-18 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-04-10 | 개시 | Citigroup | Buy |
| 2024-03-27 | 개시 | Piper Sandler | Overweight |
| 2023-02-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-14 | 개시 | BTIG Research | Buy |
| 2022-03-22 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 개시 | Morgan Stanley | Overweight |
| 2021-07-20 | 개시 | SVB Leerink | Outperform |
모두보기
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
LENZ Therapeutics: Ready To Test Its Potential (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics reports results of stockholder vote By Investing.com - Investing.com Nigeria
LENZ Therapeutics reports results of stockholder vote - Investing.com
LENZ Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock By Investing.com - Investing.com South Africa
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock - Investing.com
Two Sigma Investments LP Has $493,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Transcript : LENZ Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZLENZ Therapeutics Reports Third Quarter 2024 Financial Results - mx.advfn.com
Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
BNP Paribas Financial Markets Sells 859 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN
Deutsche Bank AG Purchases 4,370 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Holdings Boosted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Holdings Decreased by Ameriprise Financial Inc. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Analysts - Defense World
LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks
7,447 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by D. E. Shaw & Co. Inc. - Defense World
LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision - Investing.com Canada
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Northern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com
Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Tower Research Capital LLC TRC Has $54,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia
LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - Yahoo Finance
Raymond James Financial Inc. Takes $245,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Leerink Partnrs Analysts Raise Earnings Estimates for LENZ - Defense World
HC Wainwright Issues Negative Estimate for LENZ Earnings - Defense World
Leerink Partnrs Has Negative Outlook of LENZ FY2028 Earnings - Defense World
LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Positive Estimate for LENZ FY2029 Earnings - Defense World
Lenz Therapeutics inks $125M licensing deal with Lotus - Axios
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by Wells Fargo & Company MN - Defense World
LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia - marketscreener.com
LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - The Manila Times
Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of “Buy” by Brokerages - Defense World
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Market Recap Check: LENZ Therapeutics Inc (LENZ)’s Negative Finish at 25.89, Up/Down -11.03 - DWinneX
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times
LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq
First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan
Barclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Lenz Therapeutics Inc (LENZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lenz Therapeutics Inc 주식 (LENZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
| Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
1.45%
0.86%
자본화:
|
볼륨(24시간):